{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:12Z","timestamp":1791235332974,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"unspecified","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>About 20% of female patients with anti-phospholipid syndrome (APS) experience obstetric complications despite standard treatment with aspirin and heparin. Treatment with hydroxychloroquine (HCQ) was shown to reduce disease flares during pregnancy in patients with systemic lupus erythematosus and to improve pregnancy outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the impact of HCQ on live birth and obstetric complication rates in pregnant women diagnosed with APS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically searched PubMed and EMBASE databases in April 2024 for original, peer-reviewed studies on HCQ efficacy and safety in APS patients. The main outcomes measured were live births and obstetric complications, comparing HCQ plus standard therapy to standard therapy alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven observational studies met our inclusion criteria, comprising a total of 750 patients included in the meta-analysis. The overall pooled proportions of live births in the HCQ group were 89.9% (95% CI 76.5% to 96.0%; <jats:italic>I<\/jats:italic>\n                     <jats:sup>2<\/jats:sup>=81%) and 73.9% (95% CI 51.8% to 88.2%; <jats:italic>I<\/jats:italic>\n                     <jats:sup>2<\/jats:sup>=81%) in the non-HCQ-treated group. The overall pooled proportion of obstetric complications occurred in 19.3% (95% CI 9.4% to 35.4; <jats:italic>I<\/jats:italic>\n                     <jats:sup>2<\/jats:sup>=81%; four studies) of the HCQ group and 55.0% (95% CI 39.4 to 69.7; <jats:italic>I<\/jats:italic>\n                     <jats:sup>2<\/jats:sup>=79%; four studies) of the non-HCQ treated group. Treatment with HCQ was associated with higher rates of live births (OR 2.66; 95%\u2009CI 1.44 to 4.91) and lower obstetric complications (OR 0.19; 95%\u2009CI 0.19 to 0.39) compared with non-HCQ treatment. HCQ treatment during pregnancy was well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings suggest that HCQ may offer potential benefits to APS patients during pregnancy by increasing the probability of live birth rates and lowering the risk for obstetric complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>The study was registered with PROSPERO, the prospective international register of systematic reviews (identification number CRD42024574097).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005825","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:15:29Z","timestamp":1756314929000},"page":"e005825","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-0549","authenticated-orcid":false,"given":"Aya","family":"Berman","sequence":"first","affiliation":[{"name":"Dan Petah-Tikvah District at Clalit Health Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis & Hemostasis, Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"The Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Soffer","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf A","family":"Barg","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis & Hemostasis, Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Levy-Mendelovich","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis & Hemostasis, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Waldman-Radinsky","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadan","family":"Lalezari","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Klang","sequence":"additional","affiliation":[{"name":"The Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-9110","authenticated-orcid":false,"given":"Orly","family":"Efros","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2025100518351548000_11.3.e005825.1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1055\/s-0036-1592336","article-title":"Pregnancy and Antiphospholipid Syndrome","volume":"42","author":"Schreiber","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"2025100518351548000_11.3.e005825.2","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025100518351548000_11.3.e005825.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102901"},{"key":"2025100518351548000_11.3.e005825.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2011.01236.x"},{"key":"2025100518351548000_11.3.e005825.5","doi-asserted-by":"crossref","first-page":"e842","DOI":"10.1016\/S2665-9913(22)00308-3","article-title":"Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study","volume":"4","author":"Murarasu","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025100518351548000_11.3.e005825.6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025100518351548000_11.3.e005825.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"2025100518351548000_11.3.e005825.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.88"},{"key":"2025100518351548000_11.3.e005825.9","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2020.9489","article-title":"Aspirin and heparin in the treatment of recurrent spontaneous abortion associated with antiphospholipid antibody syndrome: A systematic review and meta-analysis","volume":"21","author":"Yu","year":"2021","journal-title":"Exp Ther Med"},{"key":"2025100518351548000_11.3.e005825.10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jth.15290","article-title":"Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence?","volume":"19","author":"Hamuly\u00e1k","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025100518351548000_11.3.e005825.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.01.026"},{"key":"2025100518351548000_11.3.e005825.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"2025100518351548000_11.3.e005825.13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/rheumatology\/keae168","article-title":"Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study","volume":"64","author":"Nguyen","year":"2025","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025100518351548000_11.3.e005825.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.22159"},{"key":"2025100518351548000_11.3.e005825.15","doi-asserted-by":"crossref","unstructured":"Pluma A , Hamroun S , R\u00fcegg L , et al . Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis 2025;16. doi:10.1016\/j.ard.2025.02.021","DOI":"10.1016\/j.ard.2025.02.021"},{"key":"2025100518351548000_11.3.e005825.16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030543"},{"key":"2025100518351548000_11.3.e005825.17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome","volume":"24","author":"Arachchillage","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025100518351548000_11.3.e005825.18","doi-asserted-by":"crossref","unstructured":"Dima A , Jurcut C , Chasset F , et al . Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 2022;14. doi:10.1177\/1759720X211073001","DOI":"10.1177\/1759720X211073001"},{"key":"2025100518351548000_11.3.e005825.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120157"},{"key":"2025100518351548000_11.3.e005825.20","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025100518351548000_11.3.e005825.21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00296-023-05457-5","article-title":"The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome","volume":"44","author":"Fierro","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025100518351548000_11.3.e005825.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.040"},{"key":"2025100518351548000_11.3.e005825.23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2025100518351548000_11.3.e005825.24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2021.08.004","article-title":"The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome","volume":"206","author":"Gerde","year":"2021","journal-title":"Thromb Res"},{"key":"2025100518351548000_11.3.e005825.25","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2025100518351548000_11.3.e005825.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025100518351548000_11.3.e005825.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025100518351548000_11.3.e005825.28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001239","article-title":"Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2025100518351548000_11.3.e005825.29","doi-asserted-by":"crossref","first-page":"103171","DOI":"10.1016\/j.jri.2020.103171","article-title":"Risk factors for pregnancy failure in patients with antiphospholipid antibody positivity and prior pregnancy losses: A retrospective study","volume":"141","author":"Duan","year":"2020","journal-title":"J Reprod Immunol"},{"key":"2025100518351548000_11.3.e005825.30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1632388","article-title":"Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study","volume":"47","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025100518351548000_11.3.e005825.31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10067-022-06462-y","article-title":"The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities","volume":"42","author":"Ye","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025100518351548000_11.3.e005825.32","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s10067-019-04670-7","article-title":"Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China","volume":"38","author":"Zhou","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025100518351548000_11.3.e005825.33","first-page":"1736","article-title":"Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine","volume":"29","author":"Latino","year":"2020","journal-title":"Lupus (Los Angel)"},{"key":"2025100518351548000_11.3.e005825.34","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13761","article-title":"Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review","volume":"90","author":"Hooper","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"2025100518351548000_11.3.e005825.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"2025100518351548000_11.3.e005825.36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2016.04.008","article-title":"Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome","volume":"75","author":"Bertolaccini","year":"2016","journal-title":"J Autoimmun"},{"key":"2025100518351548000_11.3.e005825.37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025100518351548000_11.3.e005825.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.09.007"},{"key":"2025100518351548000_11.3.e005825.39","unstructured":"Heads of Medicines Agencies . Final lead member state psur follow-up assessment report active substance(s): hydroxychloroquine."},{"key":"2025100518351548000_11.3.e005825.40","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S2665-9913(23)00215-1","article-title":"Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases","volume":"5","author":"Schreiber","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025100518351548000_11.3.e005825.41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","article-title":"HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"}],"updated-by":[{"DOI":"10.1136\/rmdopen-2025-005825corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T01:35:30Z","timestamp":1759714530000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/rmdopen-2025-005825"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005825","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}